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Cyclosporin A (CsA) is an immunomodulator drug that has been used in the treatment of several types of advanced 
pulmonary interstitial disease. This beneficial effect occurs mainly in circumstances in which alveolitis due to CD4 
lymphocytes is absent, suggesting that CsA acts on other types of cells. The present study was undertaken to 
determine the effect of CsA on inflammatory cytokine secretion by human alveolar macrophages (AMs). Human 
AMs were collected by bronchoalveolar lavage from four control subjects and 13 patients with interstitial lung 
disease. Purified human AMs were incubated with different concentrations of CsA (200, 20 and 2 ng ml - ‘) in the 
presence or absence of lipopolysaccharide (LPS). Interleukin-lp (IL-@), tumour necrosis factor-a (TNF-a), IL-6 
and IL-8 levels were measured in supernatants using specific enzyme-linked immunosorbent assays. It was found 
that CsA inhibits basal secretion of TNF-a and IL-S at 20 and 200 ng ml I. However, none of the different 
concentrations of CsA modified basal secretion of IL-lp nor IL-6. By contrast, a lower concentration of CsA 
(2 ng ml - ‘) inhibits LPS-stimulated secretion of all inflammatory cytokines. It is concluded that CsA exerts a 
modest effect on inflammatory cytokine production by human AMs. 
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Introduction 
Cyclosporin A (CsA) is an immunomodulatory drug used 
in the prevention of transplant rejection and in the treat- 
ment of auto-immune diseases (1). Classically, it has 
been reported that CsA exerts its immunomodulatory 
action via its effect on helper T-lymphocytes by 
inhibiting interleukin-2 synthesis (2). However, it has 
recently been described that inhibition of the activation 
of T-lymphocytes by CsA cannot account adequately 
for all the effects observed after in vivo administration of the 
drug (3). Functional modification of the mononuclear 
phagocyte system cells offers an attractive possibility 
for explaining the effects of this drug, since these cells 
participate in an essential way in antigen presentation 
and, in many cases, they are the final effecters of the 
immune system. 
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Cyclosporin A has been used successfully in the treat- 
ment of advanced interstitial lung diseases (ILD), especially 
in cases of idiopathic pulmonary fibrosis (IPF) (4-7). In 
this setting, CsA could exert indirect anti-inflammatory 
effects by inhibiting the production of lymphokines by 
helper T-cells (8). However, lymphocytes play a 
minor role in the pathogenesis of IPF; a disease 
mainly mediated by alveolar macrophages (AMs) 
and polymophonuclear leukocytes (9). Thus, another 
possible explanation for the profitable effects of CsA on 
ILD may be found in its direct anti-inflammatory effect 
on AMs. 
Alveolar macrophages are among the first line of lung 
defences encountered by pathogens inhaled into the lung 
(10) and play a role in initiating and maintaining 
an inflammatory response in the lower respiratory 
tract (11). In order to participate adequately in the 
inflammatory response, AMs synthesize and release a 
large amount of soluble mediators (i.e. hydrolytic 
enzymes, oxygen free radicals, cytokines, arachidonic 
acid metabolites) which can injure the lung parenchyma. 
Specifically, the release of inflammatory cytokines 
[interleukin -I,8 (IL-l,& tumour necrosis factor-a (TNF-a), 
IL-6 and IL-81 by AMs (12,13) is a crucial event in 
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TABLE 1. Effect of cyclosporin A (GA) on interleukin lp (IL-lp) alveolar macrophage (AM) 
secretion (pg 10 - 6 AM) 
Mean SEM P value 
Basal 
+CsA (2ngmll’) 
+ CsA (20 ng ml ~ ‘) 
+CsA (200 ng ml-‘) 
+ LPS (10 pug ml ~ ‘) 
+LPS (lO~gmll’)+CsA (2ngmll’) 
+LPS (lO~gmll’)+CsA (20ngml-‘) 
+LPS (10~gml11)+CsA(200ngml-‘) 
73.4 23.7 
84.2 28.0 0.39” 
71.1 24.3 0.39* 
102.0 35.6 0.07* 
3956.4 1278.2 <0.001* 
3826.5 1332.5 0.02? 
3853.1 1433.4 0.11-F 
5679.3 2141.6 0.037 
LPS, lipopolysaccharide. 
*P value for the comparison with basal secretion. 
tP value for the comparison with LPS-stimulated secretion. 
the pathogenesis of alveolitis, which is the first stage of 
diffuse ILD. 
The aim of the present study was to investigate the effect 
of CsA on the secretion of inflammatory cytokines (IL-l/j’, 
TNF-a, IL-6 and IL-8) by human AMs. 
Methods 
STUDY POPULATION 
All patients were informed of the technical aspects of the 
procedure, and written consent was obtained prior to the 
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FIG. 1. Effect of cyclosporin A (CsA) (200 ng ml ~ ‘) on 
interleukin-lp (IL-lp) alveolar macrophage (AM) secre- 
tion. LPS, lipopolysaccharide. 0, control; A, sarcoidosis; 
0, hypersensitivity pneumonitis; 0, idiopathic pulmonary 
fibrosis. 
bronchoalveolar lavage (BAL). None of the subjects 
smoked and none had been treated for at least 2 months 
prior to study. 
Four subjects as controls, five patients with sarcoidosis, 
three with hypersensitivity pneumonitis (HP) and five with 
IPF were studied. 
All of the control subjects displayed unexplained dry 
cough. None of the subjects had radiologic evidence of lung 
disease or altered lung function measurements. No bron- 
choscopic anomalies were observed in the pulmonary area 
in which the BAL was performed. Normal subjects were not 
included in this study for ethical reasons. 
Diagnosis of sarcoidosis was made using the following 
criteria: compatible clinical history and chest X-ray; lung or 
peripheral biopsy demonstrating non-caseating epitheloid 
granulomas with giant cell formation and a co-existing 
morphology of the parenchyma compatible with sarcoido- 
sis; no history of mycobacterial, fungal or parasitic infec- 
tions; no history of exposure to inorganic or organic 
material known to cause granulomatous lung diseases; and 
abnormal pulmonary functions with either reduced lung 
volumes or impairment in diffusing capacity. 
Diagnosis of HP was made on the basis of standard 
parameters: documented history of exposure to HP anti- 
gens; a symptomatic acute episode with chills, fever, cough 
and breathlessness 448 h after exposure to the specific 
antigen; radiologic and/or functional features of ILD; 
serum antibodies against antigens and transbronchial 
biopsy in agreement with HP. 
Diagnosis of IPF required the following: no clinical 
history of exposure to environmental agents known to 
cause ILD; no history of chronic lung infections; evidence 
of interstitial infiltrates on chest X-ray; lung physiology 
consistent with a restrictive ventilatory defect, including 
decreased lung volume, normal flow rates, and/or decreased 
single-breath carbon monoxide diffusion test; and biopsy 
evidence in each patient of interstitial pneumonitis with 
varying degrees of interstitial fibrosis without evidence of 
granulomas, vasculitis or inorganic material visualized by 
polarized light microscopy. 
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TABLE 2. Effect of cyclosporin A (CsA) on tumour necrosis factor o. (TNF-a) alveolar macrophage 
(AM) secretion (ng 10 - 6 AM) 
Mean SEM P value 
Basal 
+CsA (2 ngml-‘) 
+ CsA (20 ng ml - ‘) 
+ CsA (200 ng ml - ‘) 
+LPS (1Opgmll’) 
+LPS (lOpgmll’)+CsA (2ngml-‘) 
+LPS (lO~gmll’)+CsA (20ngml-‘) 
+LPS (lO~gmll’)+CsA (200ngmlli) 
1.62 0.28 
1.37 0.20 
1.30 0.21 
1.03 0.19 
44.16 10.46 
39.18 10.06 
41.50 9.74 
23.71 5.27 
0.204 
0.001* 
<O.OOl” 
~0~001” 
0.004t 
0.03? 
<0.001-t 
LPS, lipopolysaccharide. 
*P value for the comparison with basal secretion. 
tP value for the comparison with LPS-stimulated secretion. 
RECOVERY OF ALVEOLAR MACROPHAGES 
Alveolar macrophages were obtained by fibre-optic bron- 
choscopy with BAL. Bronchoalveolar lavage was per- 
formed according to the technical recommendations and 
guidelines for bronchoalveolar lavage of the Task Group 
on BAL of the European Society of Pneumology. Lavage 
premeditation, consisting of 0.5 mg of atropine, was 
administered 1 h earlier. The upper respiratory tract was 
anaesthetized with topical 2% lignocaine. A fibre-optic 
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FIG. 2. Effect of cyclosporin A (CsA) (200 ng ml ~ ‘) on 
tumour necrosis factor a (TNF- a) alveolar macrophage 
(AM) secretion. LPS, lipopolysaccharide. 0, control; A, 
sarcoidosis; 0, hypersensitivity pneumonitis; 0, idiopathic 
pulmonary fibrosis. 
bronchoscope (Olympus BF-10) was passed via the nose to 
the lower respiratory tract which had been anaesthetized 
locally. The instrument was wedged in a segmental bron- 
chus of the right middle lobe. A total of 200ml of sterile 
0.9% saline solution was instilled, at room temperature, in 
four aliquots of 50 ml. Fluid was recovered by gentle 
aspiration with a syringe, taking care to lose none 
of the liquid. The mixture recovered was collected in a 
siliconized bottle, previously placed in an ice bath, until 
later processing (less than 1 h later). 
The BAL fluid (BALF) obtained from the patients was 
quantified and filtered through two layers of sterile surgical 
gauze. Following this, it was centrifuged at 500 g for 10 min 
at room temperature and the supernatant was separated 
from the cell pellet. The latter was washed twice with 
phosphate-buffered saline solution (PBS; pH 7.4) and the 
cells were resuspended at a concentration of 1 x lo6 ml - i. 
Viability, determined by means of trypan blue vital exclu- 
sion stain, was >90% in all cases. Total cells were counted 
in a Neubauer chamber. In each case, several preparations 
were performed using a cytocentrifuge (Cytospin-2 
Shandon), placing 50 000 cells in each cuvette and centri- 
fuging for 7 min at 400 rpm. Using Diff-Quikm and non- 
specific esterase-stained preparations, a conventional 
differential cell count was performed on 200 cells by two 
independent observers. 
ALVEOLAR MACROPHAGE CULTURE 
Cells recovered from the BALF were centrifuged for 
35 min at 600 g on a Ficoll-Hypaque density gradient 
(Lymphoprepa, Nyergaard, Oslo, Norway) at 20°C. After 
interphase separation and two washings with PBS, cells 
were resuspended in RPM1 1640 (Sigma Chemical Co.) 
supplemented with 10% heat-inactivated fetal calf serum 
(Gibco BRL), 2 mM glutamine (Sigma Chemical Co.), 
100 U ml ~ ‘-100 pg ml ~ 1 penicillin-streptomycin (Sigma 
Chemical Co.) (complete medium). Mononuclear cells 
(5 x lo5 well- ‘) were plated on culture plates (Costar, 
Cambridge, MA, U.S.A.) in 2 ml of complete medium and 
allowed to adhere for 2 h at 37°C in 5% CO,. Non-adhering 
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TABLE 3. Effect of cyclosporin A (GA) on interleukin 6 (IL-6) a veolar macrophage (AM) secretion 1 
(ng lop6 AM) 
Mean SEM P value 
Basal 
+ CsA (2 ng ml ~ ‘) 
+ CsA (20 ng ml ~ ‘) 
+ CsA (200 ng ml ~ ‘) 
+LPS (10~gmll’) 
+LPS (lOpgmll’)+CsA (2ngmll’) 
+LPS (lO~gmll’)+CsA (20ngmll’) 
+LPS (lOpgml-‘)+CsA (200ngmll’) 
3.55 1.24 
3.81 1.39 0.29* 
3.31 1.08 0.49* 
4.03 1.58 0.1” 
58.88 12.62 <O.OOl” 
53.19 9.69 0.02? 
63.64 13.53 0.13t 
59.56 13.66 0.36t 
LPS, lipopolysaccharide. 
*P value for the comparison with basal secretion. 
f-P value for the comparison with LPS-stimulated secretion. 
cells were removed by gentle washing with media, and 2 ml 
of fresh complete medium was added for further cell 
culture. Adherent cells (AMs) were incubated alone or 
with lipopolysaccharide (LPS) (Sigma Chemical Co) 
(10 pg ml ~ ‘). CsA (Sandoz, Basel, Switzerland) was added 
at three in vivo non-toxic concentrations (200, 20 and 
2 ng ml - ‘). After 24 h at 37°C in 5% CO,, the supernatant 
was collected, centrifuged at 500 g for 10 min and stored at 
- 70°C. None of the three CsA concentrations used modi- 
fied the viability of cells (assessed by trypan blue exclusion). 
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FIG. 3. Effect of cyclosporin A (CsA) (200 ng ml- ‘) on 
interleukin-6 (IL-6) alveolar macrophage (AM) secretion. 
LPS, lipopolysaccharide. 0, control; A, sarcoidosis; 0, 
hypersensitivity pneumonitis; [7, idiopathic pulmonary 
fibrosis. 
All experiments were performed using endotoxin-free 
materials. 
CYTOKINE ASSAYS 
Interleukin-l/$ TNF-a, IL-6 and IL-8 were measured 
in AM cell culture supernatants using commercially 
available enzyme-linked immunosorbent assays (ELISA) 
(Amersham, U.K.). These ELISA kits consistently 
detected cytokine concentrations 20.3 pg ml ~ i (IL-l/Z), 
>4.8 pg ml ~ i (TNF-a), >0.35 pg ml-’ (IL-6) and 
>4.7 pg ml - i (IL-8). All samples were measured in dupli- 
cate and the results expressed in pg or ng lo6 AMs. None of 
the components of the complete culture medium (RPM1 
1640, penicillin, streptomycin, L-glutamine or fetal bovine 
serum) or CsA crossreacted in the ELISA assays. 
STATISTICAL ANALYSIS 
All data are expressed as means & SEM. For each cytokine, 
Wilcoxon’s signed-rank test for matched pairs was used to 
compare the differences in cytokine secretion between CsA- 
treated and untreated AMs; P values ~0.05 were adopted 
as significant. 
Results 
The total number of cells recovered and the differential 
count of recovered cells were similar to the data reported in 
the literature (data not shown). 
Interleukin lp secretion by AMs in the different situations 
is shown in Table 1. As expected, LPS stimulation strongly 
increased IL-lp secretion (P<O.OOl). When AMs were incu- 
bated with CsA at lower concentrations (2 ng ml ~ ‘), the 
spontaneous release of IL-lfi was not affected while LPS- 
stimulated secretion was inhibited (p=O.O2). At 20 ng ml ~ ‘, 
CsA did not modify spontaneous or LPS-stimulated secre- 
tion of IL-lb secretion by AMs. However, higher concen- 
trations of CsA (200 ng ml ~ ‘) increased LPS-stimulated 
(P=O.O3) secretion of IL-lp (Fig. 1). 
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TABLE 4. Effect of cyclosporin A (CsA) on interleukin 8 (IL-8) alveolar macrophage (AM) secretion 
(ng lop6 AM) 
Mean SEM P value 
Basal 
+CsA (2ngml-‘) 
+CsA (20ngmll’) 
+CsA (200 ng ml-‘) 
+LPS (lOpgml-‘) 
+LPS (lOpgml-‘)+CsA (2ngml-‘) 
+LPS (lOpgml-‘)+CsA (20ngml-‘) 
+LPS (lOpgml-‘)+CsA (200ngml-‘) 
353.93 66.65 
346.48 6754 0.12” 
329.28 61.33 0.03* 
268.22 64.30 <0.001* 
894.66 123.50 ~o.ool* 
806.14 120.42 o.oost 
833.80 112.49 0.027 
785.56 130.50 0.007? 
LPS, lipopolysaccharide. *P value for the comparison with basal secretion. 
-fP value for the comparison with LPS-stimulated secretion. 
Tumour necrosis factor-u secretion by AMs is depicted 
in Table 2). Lipopolysaccharide stimulation strongly 
increased TNF-a secretion (PcO.001). Spontaneous secre- 
tion of TNF-a was not affected by low concentrations of 
CsA (2 ng ml - ‘), but this dose decreased LPS-stimulated 
secretion of TNF-a (P=O.O04). Also, intermediate concen- 
trations of CsA (20 ng ml - ‘) decreased both spontaneous 
(P=O.OOl) and LPS-stimulated secretion of TNF-a 
(P=O.O3). Finally, TNF-a levels in untreated and LPS- 
stimulated AM supernatants were decreased by high 
concentrations (200 ng ml- ‘) of CsA (P<O.OOl) (Fig. 2). 
Interleukin-6 secretion by AMs in the different situations 
is shown in Table 3. As expected, LPS stimulation strongly 
increased IL-6 secretion (P<O.OOl). The addition of low 
CsA concentrations (2 ng ml - ‘) did not affect spontaneous 
secretion of IL-6 but decreased LPS-stimulated secretion 
(P= 0.02). However, at concentrations of 20 or 200 ng ml - i 
(Fig. 3) CsA failed to suppress spontaneous or LPS- 
stimulated IL-6 secretion. 
Interleukin-8 secretion by AMs is depicted in Table 4). 
Lipopolysaccharide stimulation strongly increased IL-8 
secretion (P<O.OOl). Spontaneous secretion of IL-8 was not 
affected by low concentrations of CsA (2 ng ml ~ ‘), but this 
dose decreased LPS-stimulated secretion of IL-8 (P=O.OOS). 
Also, intermediate concentrations of CsA (20 ng ml - ‘) 
decreased both spontaneous and LPS-stimulated secretion 
of IL-8 (P~0.05). Finally, IL-8 levels in untreated and 
LPS-stimulated AM supernatants were decreased by high 
concentrations of CsA (P<O.Ol) (Fig. 4). 
Discussion 
Diffuse pulmonary interstitial diseases, mainly those of 
unknown aetiology, often generate important therapeutic 
problems. Although treatment with corticosteroids, com- 
bined or not with cytotoxic immunosuppressor agents, is 
the first step in the management of patients with these 
diseases, the response to such agents is often reduced or 
null. Accordingly, in certain specific cases, treatment with 
CsA has been used empirically to try to modulate the 
immune and/or inflammatory response underlying most 
entities included in this group of diseases. However, the 
rational basis for the use of CsA in such processes is limited. 
Thus, although this immunomodulator has usually been 
considered to exert a predominant effect on helper 
T-lymphocytes, the best response to CsA has been seen in 
IPF (4-7) a disease mainly mediated by neutrophils and 
alveolar macrophages. 
These results show that CsA produced either no or 
modest decreases in cytokine production by AMs. At low 
concentrations (2 ng ml - ‘), CsA decreased stimulated 
secretion of all the inflammatory cytokines without affect- 
ing spontaneous secretion. The use of intermediate concen- 
trations of CsA (20 ng ml - ‘) decreased both basal and 
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FIG. 4. Effect of cyclosporin A (CsA) (200 ng ml - ‘) on 
interleukin-8 (IL-8) alveolar macrophage (AM) secretion. 
LPS, lipopolysaccharide. 0, control; CJ, sarcoidosis; 0, 
hypersensitivity pneumonitis; 0, idiopathic pulmonary 
fibrosis. 
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stimulated secretion of TNF-a and IL-S, without modifying 
the secretion of IL-l and IL-6. Finally, at high concen- 
trations (200 ng ml - I), CsA increased the stimulated secre- 
tion of IL-lp, did not alter that of IL-6 and decreased both 
the basal and stimulated secretion of TNF-a and IL-8. The 
inhibition exerted by this immunomodulator on TNF-a and 
IL-S secretion is concentration dependent. However, only 
the lowest concentration of CsA (2 ng ml- ‘) was able to 
inhibit the secretion of IL-6, possibly suggesting that the 
mechanism of action of CsA on the secretion of this 
molecule could be different, or that CsA might exert 
opposite actions on several intracellular processes related to 
the secretion of IL-6. The increase in the secretion of IL-lp 
at high CsA concentrations (200 ng ml - ‘) can be explained 
in terms of the peculiar processing and secretion of this 
cytokine, which accumulates in the cytoplasm of cells of the 
mononuclear phagocyte system (14). Since CsA is able to 
bind to the plasma membrane, modifying its physicochemi- 
cal properties (15), it would be possible to speculate that at 
high concentrations (200 ng ml ~ ‘), this action would elicit 
an increase in permeability and an increase in release, 
without altering the synthesis of IL-lj?. The results obtained 
in this study cannot be compared with those reported in the 
literature since, after a profound review, the authors found 
no references to the action of CsA on inflammatory 
cytokine secretion by human AMs. However, the present 
results are in agreement with the data relating to the action 
of CsA on the secretion of IL-l, TNF and IL-6 by other 
cells of the human mononuclear phagocyte system (16-20). 
Further and larger studies are needed to confirm these 
results and to study the mechanism of this CsA action on 
macrophages. 
The second interesting aspect of this study is the demon- 
stration of the CsA effect on the AMs of normal and ILD 
patients. Accordingly, the drug may be effective in many 
types of ILD accompanied by macrophage activation. 
Specifically, these data support the notion of a direct effect 
of CsA on human AMs as an explanation for the improve- 
ment observed in patients with IPF treated with this 
immunomodulator. In view of the undebatable role of IL-S 
in the pathogenesis of IPF (9,21,22) and the effect of CsA 
on the production of IL-S, this immunomodulator could 
offer a novel and selective approach for future treatment of 
this type of patients (21). 
The last aspect of interest to emerge from this study is 
related to the ability of CsA to decrease stimulated secre- 
tion of inflammatory cytokines. As systemic administration 
of CsA did not achieve effective concentrations in the lower 
respiratory tract (23) it is possible that the administration 
of the drug through other routes could elicit effective 
concentrations in the alveolo-interstitial region (23-26). In 
this sense, it should be stressed that current clinical 
investigations into the use of aerosolized CsA for the 
treatment of patients undergoing lung transplantation 
are quite advanced (27,28). Additionally, it has been 
observed that the efficiency of this treatment is 
correlated with suppression of the production of inflamma- 
tory cytokines (29). As is evident, it would be interesting 
to study the use of aerosolized CsA for the treatment 
of ILD. 
Fathman CG, Myers BD. Cyclosporine therapy for 
autoimmune disease. N Engl J Med 1992; 326: 16933 
1695. 
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